Your browser doesn't support javascript.
Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification.
Baddock, Hannah T; Brolih, Sanja; Yosaatmadja, Yuliana; Ratnaweera, Malitha; Bielinski, Marcin; Swift, Lonnie P; Cruz-Migoni, Abimael; Fan, Haitian; Keown, Jeremy R; Walker, Alexander P; Morris, Garrett M; Grimes, Jonathan M; Fodor, Ervin; Schofield, Christopher J; Gileadi, Opher; McHugh, Peter J.
  • Baddock HT; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
  • Brolih S; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
  • Yosaatmadja Y; Centre for Medicines Discovery, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
  • Ratnaweera M; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
  • Bielinski M; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK.
  • Swift LP; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
  • Cruz-Migoni A; Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
  • Fan H; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.
  • Keown JR; Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford OX3 7BN, UK.
  • Walker AP; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.
  • Morris GM; Department of Statistics, University of Oxford, 24-29 St Giles', Oxford OX1 3LB, UK.
  • Grimes JM; Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford OX3 7BN, UK.
  • Fodor E; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot OX11 0DE, UK.
  • Schofield CJ; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.
  • Gileadi O; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK.
  • McHugh PJ; Centre for Medicines Discovery, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
Nucleic Acids Res ; 50(3): 1484-1500, 2022 02 22.
Article in English | MEDLINE | ID: covidwho-1624985
ABSTRACT
The SARS-CoV-2 coronavirus is the causal agent of the current global pandemic. SARS-CoV-2 belongs to an order, Nidovirales, with very large RNA genomes. It is proposed that the fidelity of coronavirus (CoV) genome replication is aided by an RNA nuclease complex, comprising the non-structural proteins 14 and 10 (nsp14-nsp10), an attractive target for antiviral inhibition. Our results validate reports that the SARS-CoV-2 nsp14-nsp10 complex has RNase activity. Detailed functional characterization reveals nsp14-nsp10 is a versatile nuclease capable of digesting a wide variety of RNA structures, including those with a blocked 3'-terminus. Consistent with a role in maintaining viral genome integrity during replication, we find that nsp14-nsp10 activity is enhanced by the viral RNA-dependent RNA polymerase complex (RdRp) consisting of nsp12-nsp7-nsp8 (nsp12-7-8) and demonstrate that this stimulation is mediated by nsp8. We propose that the role of nsp14-nsp10 in maintaining replication fidelity goes beyond classical proofreading by purging the nascent replicating RNA strand of a range of potentially replication-terminating aberrations. Using our developed assays, we identify drug and drug-like molecules that inhibit nsp14-nsp10, including the known SARS-CoV-2 major protease (Mpro) inhibitor ebselen and the HIV integrase inhibitor raltegravir, revealing the potential for multifunctional inhibitors in COVID-19 treatment.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Genome, Viral / Viral Nonstructural Proteins / Genomic Instability / Drug Evaluation, Preclinical / Exoribonucleases / Viral Regulatory and Accessory Proteins / SARS-CoV-2 Type of study: Prognostic study Topics: Traditional medicine Language: English Journal: Nucleic Acids Res Year: 2022 Document Type: Article Affiliation country: Nar

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Genome, Viral / Viral Nonstructural Proteins / Genomic Instability / Drug Evaluation, Preclinical / Exoribonucleases / Viral Regulatory and Accessory Proteins / SARS-CoV-2 Type of study: Prognostic study Topics: Traditional medicine Language: English Journal: Nucleic Acids Res Year: 2022 Document Type: Article Affiliation country: Nar